Percutaneous caffeine application in the treatment of neonatal apnoea

Amato, Maurizio; Isenschmid, M.; Hüppi, Petra Susan

doi:10.1007/bf02072214

Cited by 27 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[38] In most of these trials, apnea is defined as cessation of breathing for >20 seconds, or <20 seconds accompanied by bradycardia, defined as a heart rate of <100 beats/minute. While shown to be effective about a decade ago, [100] percutaneous application of caffeine to treat AOP has not caught on in clinical practice due to the lack of a standardized, commercially available preparation, and also the difficulty with accurate administration with this type of dosage form.…”

Section: Clinical Trials With Caffeinementioning

confidence: 98%

Treatment of Apnea of Prematurity

Bhatt‐Mehta

Schumacher

2003

Pediatric Drugs

View full text Add to dashboard Cite

In the last decade, knowledge regarding the neurodevelopment and functional aspects of the respiratory centers during postnatal maturation has increased substantially. However, an increase in such knowledge has not provided a basis for change in practice. The diagnosis of apnea of prematurity (AOP) is one of exclusion. All causes of secondary apnea must be ruled out before initiating treatment for AOP. Treatment will depend on the etiology as well as effectiveness and tolerability of the treatment by the patient. The primary goal of any treatment of AOP is to prevent the frequency of apnea lasting >20 seconds, and/or those that are shorter, but associated with cyanosis and bradycardia. The clinical management of AOP is not much different today than it was two decades ago, with pharmacologic and nonpharmacologic treatment options remaining the mainstay of therapy. Methylxanthines are still the most widely used pharmacologic agents. Due to the wider therapeutic index of caffeine and ease of once daily administration, it should be the preferred agent. Doxapram, or nonpharmacologic treatment measures such as nasal continuous positive airway pressure, may be considered in infants who are unresponsive to methylxanthine treatment alone. Treatment should be continued until there is complete resolution of apnea, and for some time thereafter. The choice of method for weaning treatment remains one of individual physician preference. Discharge from hospital after apnea requires close monitoring and some infants will require home apnea monitors. The decision to provide a home apnea monitor should be individualized for each patient, depending on the effectiveness of treatment and clinical response.

show abstract

Section: Clinical Trials With Caffeinementioning

confidence: 98%

Treatment of Apnea of Prematurity

Bhatt‐Mehta

Schumacher

2003

Pediatric Drugs

View full text Add to dashboard Cite

show abstract

“…Caffeine was chosen as the model drug for its therapeutic [5][6] and cosmetic applications. 7 Caffeine is commonly used topically in cosmetics for its stimulating activity on fat metabolism and, in therapy, for the treatment of headache and neonatal apnea.…”

Section: -4mentioning

confidence: 99%

Release and permeation kinetics of caffeine from bioadhesive transdermal films

Nicoli¹,

Colombo

2005

AAPS J

View full text Add to dashboard Cite

The aim of this work was to investigate, in vitro, the kinetics of release and permeation of caffeine, chosen as model drug, from bioadhesive transdermal films. These films are not self-adhesive but become adhesive when applied to wet skin. Permeation experiments were performed from films with different drug loadings using rabbit ear skin as barrier. In order to characterize the release kinetics of caffeine from the film, a polyethylene membrane, impregnated with isopropyl myristate was employed. The data obtained in the present work suggest that caffeine release from transdermal bioadhesive films was controlled either by the permeability characteristics of the skin or by the film itself, depending on drug loading. When drug loading is low (ie, caffeine is dissolved in the polymers constituting the film), the control resides in the skin. When caffeine loading exceeds its solubility in the film, the permeation profile is not linear, but shows a sort of burst effect in the early times of permeation, probably owing to the presence of solid drug and/or to a certain degree of ''conserved supersaturation'' in the solid phase.

show abstract

“…Caffeine is commonly used in cosmetics for its stimulating activity on fat metabolism and also in therapy for the treatment of headache and neonatal apnea [1,2].…”

Section: Introductionmentioning

confidence: 99%

Bioadhesive Transdermal Film Containing Caffeine

Nicoli¹,

Amoretti²,

Colombo³

2004

Skin Pharmacol Physiol

View full text Add to dashboard Cite

The aim of this work was to investigate in vitro the transdermal permeation of caffeine from a new bioadhesive film, using rabbit ear skin as a barrier. The effects of film composition and of the presence of penetration enhancers in the formulation were studied. The obtained fluxes were compared with those shown by commercial formulations. The results obtained indicate that the bioadhesive film gave rise to a higher transdermal permeation compared to a commercial gel and to a saturated solution of caffeine in water. Additionally, the film did not present the typical time lag of solution and gel. Another peculiar feature of the film is that the percentage of permeated active substance is much higher than that obtained from commercial formulations. Finally, it was possible to modulate caffeine permeation from the film by adding different enhancers/solvents.

show abstract

Percutaneous caffeine application in the treatment of neonatal apnoea

Cited by 27 publications

References 10 publications

Treatment of Apnea of Prematurity

Treatment of Apnea of Prematurity

Release and permeation kinetics of caffeine from bioadhesive transdermal films

Bioadhesive Transdermal Film Containing Caffeine

Contact Info

Product

Resources

About